OTC · Biotechnology

Idorsia Ltd (IDRSF) Stock

$8.00 +0.00% OTC: IDRSF Healthcare

Established in 2017 and based in Allschwil, Switzerland, Idorsia Ltd operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs. The company's diverse clinical development pipeline targets various therapeutic areas, including central nervous system (CNS), cardiovascular, and immunological disorders, alongside treatments for rare (orphan) diseases.

Valuation

MetricValue
Price$8.00
Market Cap$2.04B
P/E Ratio-4.74
P/B Ratio-1.35
P/S Ratio8.17
EPS (TTM)$-0.52
52-Week High$8.19
52-Week Low$3.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE27.56%
ROA-65.85%
ROCE-73.48%
Gross Margin61.89%
Operating Margin-121.59%
Net Margin-158.28%
Debt/Equity-1.12
Current Ratio1.60

Annual Financials (USD)

Metric20212022202320242025
Revenue$35.0M$97.0M$152.0M$113.0M$221.0M
Operating Profit$-613.0M$-803.0M$-255.0M$-232.0M$-116.0M
Net Profit$-635.0M$-828.0M$-298.0M$-264.0M$-112.0M
EPS$-3.77$-4.67$-1.67$-1.45$-0.52
Op Margin-1734.2%-826.9%-167.4%-206.2%-52.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.5B$904.0M$500.0M$506.0M$466.0M
Total Liabilities$1.4B$1.6B$1.5B$1.7B$1.6B
Cash$101.0M$146.0M$145.0M$105.0M$87.0M
Borrowings$1.2B$1.2B$1.2B$1.3B$1.3B

Latest News

Idorsia Ltd (IDRSF) (H1 2026) Earnings Call Highlights: QUVIVIQ Surges 62% and Pipeline Advances GuruFocus.com · Aug 1, 2026 QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth GlobeNewswire · Jul 30, 2026 Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant GlobeNewswire · Jul 27, 2026 Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call GlobeNewswire · Jul 23, 2026 Idorsia appoints Roland Wandeler as Chief Executive Officer GlobeNewswire · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-590.0M$-859.0M$-629.0M$-370.0M$-153.0M
Investing Cash Flow$-84.0M$717.0M$623.0M$287.0M$-10.0M
Financing Cash Flow$0$0$0$0$-16.0M
Net Cash Flow$-39.0M$45.0M$-1.0M$-39.0M$-18.0M
Free Cash Flow$-621.0M$-886.0M$-639.0M$-388.0M$-167.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.04
EV / EBITDA-15.39
FCF Yield-8.60%
Quick Ratio1.08
Interest Coverage-5.15
Return 1Y122.84%
Return 3Y10.34%
Return 5Y—

Ownership

Insiders Held29.59%
Institutions Held26.72%
Institutions Float Held37.95%
Institutional HolderSharesReport Date
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund4,663,1282026-06-30
Fidelity Select Portfolios-Select Biotechnology Portfolio2,174,2832026-06-30
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund1,367,2862026-06-30
iShares Trust-iShares Core MSCI EAFE ETF1,156,2962026-06-30
Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund899,6242026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARRJFArjo AB (publ) $2.74 +0.00% 19.10 $746.29M 3.65%
ASCLFAscletis Pharma Inc. $1.42 +0.00% -20.87 $1.49B 0.00%
BPMUFBasilea Pharmaceutica AG $60.28 +0.00% 19.58 $746.00M 0.00%
INRLFValneva SE $2.43 -7.25% -2.67 $460.84M 0.00%
LFTSFLifeTech Scientific Corporation $0.23 +0.00% 38.30 $1.03B 0.00%

About Idorsia Ltd

Established in 2017 and based in Allschwil, Switzerland, Idorsia Ltd operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs. The company's diverse clinical development pipeline targets various therapeutic areas, including central nervous system (CNS), cardiovascular, and immunological disorders, alongside treatments for rare (orphan) diseases. Idorsia maintains a portfolio of strategic alliances: a joint development and commercialization agreement with Janssen Biotech Inc. for aprocitentan and its related products; a licensing deal with Mochida Pharmaceutical for the supply, co-development, and co-marketing of daridorexant; and a collaboration with Hoffman-La Roche Inc. to advance and market cancer immunotherapy compounds. Additionally, Idorsia is partnering with Antares Pharma, Inc. to create a self-administered drug device product for Selatogrel, and with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is currently undergoing Phase II clinical trials for epilepsy.

Idorsia Ltd is headquartered in CH.

Idorsia Ltd (IDRSF) stock trades at $8.00 with a market capitalization of $2.04B. The stock is valued at a price-to-earnings (P/E) ratio of -4.74, price-to-book of -1.35, price-to-sales of 8.17. Over the past 52 weeks the stock has ranged between $3.30 and $8.19, and currently trades 2.3% below its 52-week high.

On profitability, Idorsia Ltd generates a return on equity (ROE) of 27.56% — well above the market average, a sign of a high-quality business, return on capital employed of -73.48%, an operating margin of -121.59%, a net profit margin of -158.28%.

Official website: www.idorsia.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides